Gene-free Viral-like particles (VLPs) offer a safer alternative to inactivating or weakening viral strains for traditional vaccines. VLP-based vaccinations without adjuvants have been found to promote humoral and cellular immunity

Moataz Dowaidar
DOI: https://doi.org/10.31219/osf.io/9dvut
2021-06-10
Abstract:Nanotechnology and protein engineering helped revolutionize the invention and upgrading of immunization carriers, as well as medicine packaging and delivery systems. Viruses have been considered functioning NPs in the 21st century. This nano-structure may deliver antigens and medications to multiple locations throughout tissues and organs. Gene-free Viral-like particles (VLPs) offer a safer alternative to inactivating or weakening viral strains for traditional vaccines. This allows for the development of VLPs that can contain polyvalent antigenic structures that can also contain antigenic chemicals to target tissues. Also, they're immunogens. VLPs have also been shown to be excellent adjuvants. VLP-based vaccinations without adjuvants have been found to promote humoral and cellular immunity via the MHC class I and II route in some cases.Also used as therapeutic vaccines, presenting patients' own antigens and assisting them in the fight against chronic and metabolic diseases, as well as various types of cancers. Several vaccines created from VLP have been approved or are being tested in the clinical setting. More investigation is needed to fully assess the effectiveness, bad effects, difficulties, and benefits of VLP-based vaccinations when used for different cancers.Despite technical obstacles such as molecules appearing correctly on the particle surface, current research has provided substantial amounts of knowledge that may assist to alleviate these challenges. One option discovered in our lab is to add a sortase recognition motif (LPXTG) to the surface of distinct VLPs that may be exposed. To protect the VLP integrity, it allows proteins to be attached to the VLP surface. Use of VLP external surfaces to transport medications to a specific cell or tissue in order to treat an illness. The VLP's surface can be manipulated in order to optimize the VLP's efficacy. In order to deliver this complex to a specified target, it must be fused with molecules on the surface. Despite the fact that VLP-based vaccinations have been successful in helping to prevent disease, more work is needed to reach the optimum condition.
What problem does this paper attempt to address?